Skip to content
Nonprofiteer
← FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND

Form 990 for tax year 2024

Filed by FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS FIND.

Totals

Total revenue
$49,306,331
Total expenses
$56,828,646
Contributions and grants received
$46,591,810
Grants paid
$12,782,246
Program service revenue
$0
Investment income
$2,412,155
Other revenue
$302,366
Total assets, end of year
$51,274,531
Total liabilities, end of year
$42,634,091
Net assets or fund balances, end of year
$8,640,440
Program services expenses (Part IX)
$46,121,006
Management and general expenses
$10,011,541
Fundraising expenses
$696,099
Program service expenses (Part III)
$46,121,006

Program services were 81.2% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1e · Government grants (contributions)

    $20,189,970

  • 1f · All other contributions, gifts and grants

    $26,401,840

  • 2f · All other program service revenue

    total $0 · related or exempt $0 · unrelated business $0 · excluded $0

  • 3 · Investment income

    total $2,412,155 · excluded $2,412,155

  • 6c · Rental income or loss

    real property $0 · personal property $0

  • 7c · Gain or loss

    securities $0 · other assets $0

  • 11a · Other revenue: commission on tax deduction

    total $27,171 · excluded $27,171

  • 11b · Other revenue: Other Income

    total $275,195 · excluded $275,195

  • 11d · All other revenue

    total $0 · related or exempt $0 · unrelated business $0 · excluded $0

  • 11e · Other revenue, total

    $302,366

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $977,323 · program services $977,323

  • 3 · Grants to foreign organizations and individuals

    total $11,804,923 · program services $11,804,923

  • 5 · Compensation of officers, directors and key employees

    total $2,867,137 · program services $1,690,617 · management and general $997,484 · fundraising $179,036

  • 7 · Other salaries and wages

    total $14,140,314 · program services $11,983,608 · management and general $1,911,358 · fundraising $245,348

  • 8 · Pension plan contributions

    total $1,366,163 · program services $1,058,410 · management and general $287,746 · fundraising $20,007

  • 9 · Other employee benefits

    total $732,173 · program services $481,998 · management and general $250,175

  • 10 · Payroll taxes

    total $1,442,408 · program services $1,142,324 · management and general $276,543 · fundraising $23,541

  • 11a · Fees: management

    total $274,641 · program services $144,889 · management and general $129,752

  • 11b · Fees: legal

    total $806,130 · program services $37,198 · management and general $768,932

  • 11c · Fees: accounting

    total $464,632 · program services $97,683 · management and general $366,949

  • 11g · Fees: other

    total $0 · program services $0 · management and general $0 · fundraising $0

  • 13 · Office expenses

    total $439,254 · program services $392,361 · management and general $46,893

  • 14 · Information technology

    total $1,779,194 · program services $1,024,796 · management and general $754,398

  • 16 · Occupancy

    total $1,400,807 · program services $10,118 · management and general $1,390,689

  • 17 · Travel

    total $2,683,118 · program services $1,842,613 · management and general $812,395 · fundraising $28,110

  • 19 · Conferences, conventions and meetings

    total $567,402 · program services $465,227 · management and general $102,175

  • 23 · Insurance

    total $35,903 · program services $0 · management and general $35,903

  • 24a · Other expenses: Project contractor

    total $13,202,348 · program services $11,978,946 · management and general $1,023,345 · fundraising $200,057

  • 24b · Other expenses: EQUIPMENT & SUPPLIES

    total $1,169,633 · program services $1,000,991 · management and general $168,642

  • 24c · Other expenses: foreign exchange losses

    total $680,893 · program services $0 · management and general $680,893

  • 24d · Other expenses: TRANSLATION & SPONSORSHIP

    total -$5,750 · program services -$13,019 · management and general $7,269

  • 24e · All other expenses

    total $0 · program services $0 · management and general $0 · fundraising $0

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $13,290,319 · end of year $30,745,582

  • 2 · Savings and temporary cash investments

    beginning of year $59,797,621 · end of year $9,422,473

  • 3 · Pledges and grants receivable

    beginning of year $0 · end of year $0

  • 4 · Accounts receivable

    beginning of year $6,220,098 · end of year $8,838,243

  • 5 · Loans and receivables from officers and key people

    beginning of year $0 · end of year $0

  • 6 · Loans and receivables from disqualified persons

    beginning of year $0 · end of year $0

  • 7 · Other notes and loans receivable

    beginning of year $0

  • 8 · Inventories for sale or use

    beginning of year $0

  • 9 · Prepaid expenses and deferred charges

    beginning of year $1,814,846 · end of year $2,274,612

  • 10a · Land, buildings and equipment: cost or other basis

    $6,989

  • 10b · Land, buildings and equipment: accumulated depreciation

    $0

  • 10c · Land, buildings and equipment, net

    beginning of year $6,989 · end of year $6,989

  • 11 · Investments: publicly traded securities

    beginning of year $0

  • 12 · Investments: other securities

    beginning of year $0

  • 13 · Investments: program-related

    beginning of year $0

  • 14 · Intangible assets

    beginning of year $0

  • 15 · Other assets

    beginning of year $287,429 · end of year -$13,368

  • 17 · Accounts payable and accrued expenses

    beginning of year $11,866,468 · end of year $7,587,172

  • 18 · Grants payable

    beginning of year $0 · end of year $0

  • 19 · Deferred revenue

    beginning of year $53,388,079 · end of year $35,046,919

  • 20 · Tax-exempt bond liabilities

    beginning of year $0

  • 21 · Escrow or custodial account liability

    beginning of year $0

  • 22 · Loans and payables to officers and key people

    beginning of year $0 · end of year $0

  • 23 · Secured mortgages and notes payable

    beginning of year $0

  • 24 · Unsecured notes and loans payable

    beginning of year $0

  • 25 · Other liabilities

    beginning of year $0 · end of year $0

  • 27 · Net assets without donor restrictions

    beginning of year $10,660,263 · end of year $6,645,902

  • 28 · Net assets with donor restrictions

    beginning of year $5,502,492 · end of year $1,994,538

Mission and programs · 2024

Mission

FIND IS AN INTERNATIONAL NON-PROFIT ORGANIZATION THAT ENABLES THE DEVELOPMENT AND DELIVERY OF MUCH-NEEDED DIAGNOSTIC TESTS FOR POVERTY-RELATED DISEASES. FIND ACTS AS A BRIDGE BETWEEN EXPERTS IN TECHNOLOGY DEVELOPMENT, POLICY AND CLINICAL CARE, REDUCING BARRIERS TO INNOVATION AND EFFECTIVE IMPLEMENTATION OF DIAGNOSTIC SOLUTIONS IN LOW-AND-MIDDLE-INCOME COUNTRIES.

Activities or mission (Part I)

THE DEVELOPMENT AND IMPLEMENTATION OF NEW, LOW COST DIAGNOSTICS FOR INFECTIOUS DISEASES FOR USE IN LOW-RESOURCE AREAS.

  • See schedule O

    Expenses $13,927,035 · Grants $6,601,315

  • See schedule O

    Expenses $5,232,718 · Grants $422,632

  • See schedule O

    Expenses $4,890,020 · Grants $627,673

  • Neglected Tropical Diseases (Expenses $4,890,019) NT-P19-003 Chagas Diagnostics Market Sizing Model NT-P16-001 HAT diagnostic algorithm for South Sudan NT-P18-002 INtermediary field evalution report including the RDT performance against the reference standard NT-P19-003 Market Landscape Report of Diagnostic Products for Chagas Disease NT-P18-002 Report detailing the economic analysis of using the SCH CAA RDT instead of current diagnostic tools NT-P16-001 South Sudan HAT Access Database NT-P23-004 Test Directory for Visceral Leishmaniosis Medical Affairs Department (Expenses $4,108,156) Administrative clinical activities Womens Health Department (Expenses $3,248,296) WH-P23-001 Advancing Self collection for HPV testing as a primary cervical cancer screening strategy in sub-saharan Africa WH-P23-001 Assessing feasibility and effectiveness of point-of-care limited HPV genotype tests in cervical cancer screening: a modelling study WH-P23-001 Assessing Feasibility and efficiency of limited HPV genotype targets in cervical cancer screening for sub-saharan Africa WH-P23-001 Human Papillomavirus self-sampling versus provider-sampling in LMIC countries WH-P24-001 Technology Landscape of tools for Anaemia at Primary Health Centers WH-P23-001 Towards 70% cervical cancer screening coverage WH-P23-001 TPPs and relevance of community engagement Pandemic Threats (Expenses $3,232,156) PT-P24-003 Chikungunya test directory PT-P22-006 Diagnostic Accuracy of Three Mpox Lateral Flow Assays for Antigen Detection in the Democratic Republic of Congo and the United Kingdom PT-P22-005 DNO Analysis for Lassa and Yelloe fever in Nigeria PT-P24-002 DxConnect test directory for Lassa PT-P24-002 DxConnect test directory for Nipah PT-P22-006 Evaluation of the diagnostic accuracy and analytical sensitivity of the novel Xpert Mpox (Cepheid) and STANDARD M10 MPX/OPX (SD Biosensor) molecular point-of-care assays for the detection of Mpox virus in skin lesion swabs and upper-respiratory swab sa PT-P24-001 Filovirus Landscape PT-P23-002 i-MCM-Net Mapping Document PT-P24-002 Lassa landscape Manuscript PT-P21-001 License Agreement for Yellow Fever Ag NS1 RDT PT-P24-004 Mpox test directory PT-P24-004 Mpox test tracker PT-P23-002 PDxRI PT-P22-007 Viral Hemorrhagic Fever Strategic Plan PT-P23-002 WHS Roadmap for 100DM for Diagnostics meeting report Antimicrobial Resistance (Expenses $2,773,685) AM-P22-002 A call to bridge the diagnostic gap: diagnostic solutions for neonatal sepsis in low- and middle-income countries FE-P18-003 A Qualitative Thematic Synthesis Study with a discussion of Intervention Design to explore drivers of adherence to prescription in four sites in India AM-P21-001 Affordable blood culture systems from China: in vitro evaluation for use in resource-limited settings AM-P24-001 Antimicrobial Stewardship Modules AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 30 health facilities in India AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in 10 Counties in Kenya AM-P23-001 Assessment of Antimicrobial Resistance Diagnostic Capacity and Antibiotic Use in Kenya AM-P21-001 Blood culture bottles remain efficient months after their expiration date: Implications for low- and middle-income countries. AM-P22-002 Call for public consultation: Target product profile for tests of neonatal sepsis and possible serious bacterial infections in newborns and young infants (final TPP currently in clearance) FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa FE-P18-003 Cost-Effectiveness of Test-and-Treat Strategies to Reduce the Antibiotic Prescription Rate for Acute Febrile Illness in Primary Healthcare Clinics in Africa AM-P22-003 Development of a Novel Fluorescent-Based Lateral Flow Assay for the Detection of Neisseria gonorrhoeae at the Point of Care AM-P22-003 Evaluation of a novel point-of-care lateral flow assay screening for Neisseria gonorrhoeae infection among pregnant women in Zimbabwe AM-P24-001 Guidelines on Prudent Use of Antimicrobials in Animals FE-P18-003 Impact of a package of point-of-care diagnostic tests, a clinical diagnostic algorithm and adherence training on antibiotic prescriptions for the management of non-severe acute febrile illness in primary health facilities during the COVID-19 pandemic in B AM-P22-003 Implementation considerations for a point-of-care Neisseria gonorrhoeae rapid diagnostic test at primary healthcare level in South Africa: a qualitative study AM-P23-006 Investment case for the use of diagnostics for enhancing STI management in South Africa AM-P23-006 Modeling the impact and cost of a culture-dependent molecular test for antimicrobial resistance in resource-limited settings AM-P22-002 Multicentre external validation of the Neonatal Healthcare-associated infectiOn Prediction (NeoHoP) score: a retrospective case-control study AM-P24-001 National AMR Surveillance Report AM-P22-003 Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation AM-P23-006 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-002 Potential health and cost impacts of a point-of-care test for neonatal sepsis and possible serious bacterial infections in infants: a modeling analysis in two settings AM-P22-004 Progress made in digitalizing antimicrobial resistance surveillance in a One Health approach in Kenya AM-P21-001 Rapid bacterial identification and resistance detection in positive blood cultures from patients with sepsis in Harare, Zimbabwe: evaluation of a low complexity molecular diagnostic platform AM-P22-003 Usability of a novel lateral flow assay for the point-of-care detection of Neisseria gonorrhoeae: A qualitative time-series assessment among healthcare workers in South Africa

    Expenses $22,071,233 · Grants $5,130,626

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Ayoade Alakija

    CHAIRMAN OF THE BOARD

    Total calculated
    $0
    Hours/week
    1
  • David Heymann

    MEMBER OF THE BOARD

    Total calculated
    $0
    Hours/week
    1
  • Frutiger Christian

    MEMBER OF THE BOARD

    Total calculated
    $0
    Hours/week
    1
  • Kamineni Shobana

    MEMBER OF THE BOARD

    Total calculated
    $0
    Hours/week
    1
  • Marcel Tanner

    MEMBER OF THE BOARD

    Total calculated
    $0
    Hours/week
    1
  • Michele Costaforlaz

    MEMBER OF THE BOARD

    Total calculated
    $0
    Hours/week
    1
  • Precious Matsoso

    MEMBER OF THE BOARD

    Total calculated
    $0
    Hours/week
    1
  • Rick Arthur Bright

    MEMBER OF THE BOARD (THRU 8/2024)

    Total calculated
    $0
    Hours/week
    1
  • Soumya Swaminathan

    MEMBER OF THE BOARD (THRU 8/2024)

    Total calculated
    $0
    Hours/week
    1
  • Cassandra Kelly-Cirino

    VP, HEALTH PROGRAMMES (thru 8/24)

    Total calculated
    $236,404
    From this org
    $191,471
    From related orgs
    $0
    Other
    $44,933
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $191,471
    Bonus
    $0
    Other
    $0
    Deferred
    $38,430
    Nontaxable benefits
    $6,503
    Filer's total
    $236,404
  • Dayo Adetifa

    CHIEF TRANSFORMATION OFFICER/CEO

    Total calculated
    $173,587
    From this org
    $138,966
    From related orgs
    $0
    Other
    $34,621
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $138,966
    Bonus
    $0
    Other
    $0
    Deferred
    $34,621
    Nontaxable benefits
    $0
    Filer's total
    $173,587
  • Marta Fernandez Suarez

    CHIEF TECHNOLOGY OFFICER (thru 10/24)

    Total calculated
    $356,565
    From this org
    $285,980
    From related orgs
    $0
    Other
    $70,585
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $285,980
    Bonus
    $0
    Other
    $0
    Deferred
    $56,899
    Nontaxable benefits
    $13,686
    Filer's total
    $356,565
  • Norma Torres

    CHIEF OPERATING OFFICER (thru 5/24)

    Total calculated
    $229,953
    From this org
    $215,973
    From related orgs
    $0
    Other
    $13,980
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $215,973
    Bonus
    $0
    Other
    $0
    Deferred
    $13,980
    Nontaxable benefits
    $0
    Filer's total
    $229,953
  • Sergio Carmona

    CHIEF MEDICAL OFFICER (thru 9/24)

    Total calculated
    $343,382
    From this org
    $284,240
    From related orgs
    $0
    Other
    $59,142
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $254,041
    Bonus
    $30,199
    Other
    $0
    Deferred
    $54,619
    Nontaxable benefits
    $4,523
    Filer's total
    $343,382
  • Sharon Saacks

    SENIOR DIRECTOR, PROGRAMME OPERATIONS (thru 7/24)

    Total calculated
    $269,143
    From this org
    $230,858
    From related orgs
    $0
    Other
    $38,285
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $145,852
    Bonus
    $0
    Other
    $85,006
    Deferred
    $38,285
    Nontaxable benefits
    $0
    Filer's total
    $269,143
  • William Rodriguez

    CHIEF EXECUTIVE OFFICER (thru 6/24)

    Total calculated
    $223,051
    From this org
    $197,568
    From related orgs
    $0
    Other
    $25,483
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $197,568
    Bonus
    $0
    Other
    $0
    Deferred
    $25,483
    Nontaxable benefits
    $0
    Filer's total
    $223,051
  • Willo Brock

    EXECUTIVE VP, EXTERNAL AFFAIRS (thru 6/24)

    Total calculated
    $163,705
    From this org
    $163,705
    From related orgs
    $0
    Other
    $0
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $163,705
    Bonus
    $0
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $163,705
  • Darryl English

    DEPUTY DIRECTOR, FINANCE (THRU 11/24)

    Total calculated
    $414,021
    From this org
    $342,536
    From related orgs
    $0
    Other
    $71,485
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $342,536
    Bonus
    $0
    Other
    $0
    Deferred
    $71,485
    Nontaxable benefits
    $0
    Filer's total
    $414,021
  • Kevin Tetteh

    DIRECTOR, MALARIA FEVER PROGRAMME

    Total calculated
    $224,954
    From this org
    $181,958
    From related orgs
    $0
    Other
    $42,996
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $181,958
    Bonus
    $0
    Other
    $0
    Deferred
    $42,996
    Nontaxable benefits
    $0
    Filer's total
    $224,954
  • Sanjay Sarin

    VP, ACCESS (thru 10/24)

    Total calculated
    $232,372
    From this org
    $232,372
    From related orgs
    $0
    Other
    $0
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $232,372
    Bonus
    $0
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $0
    Filer's total
    $232,372
  • Beatrice Mouton

    DIRECTOR, HUMAN RESOURCES

    Total calculated
    $313,006
    From this org
    $260,701
    From related orgs
    $0
    Other
    $52,305
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $260,701
    Bonus
    $0
    Other
    $0
    Deferred
    $44,367
    Nontaxable benefits
    $7,938
    Filer's total
    $313,006
  • Brooke Nichols

    SENIOR DIRECTOR, IMPACT

    Total calculated
    $296,689
    From this org
    $265,429
    From related orgs
    $0
    Other
    $31,260
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $265,429
    Bonus
    $0
    Other
    $0
    Deferred
    $31,260
    Nontaxable benefits
    $0
    Filer's total
    $296,689
  • Maria Cecilia Ferreyra Arellano

    Director of AMR Programme

    Total calculated
    $250,024
    From this org
    $213,012
    From related orgs
    $0
    Other
    $37,012
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $213,012
    Bonus
    $0
    Other
    $0
    Deferred
    $30,675
    Nontaxable benefits
    $6,337
    Filer's total
    $250,024
  • Morten Ruhwald

    DIRECTOR, TUBERCULOSIS PROGRAMME

    Total calculated
    $298,773
    From this org
    $244,800
    From related orgs
    $0
    Other
    $53,973
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $244,800
    Bonus
    $0
    Other
    $0
    Deferred
    $44,029
    Nontaxable benefits
    $9,944
    Filer's total
    $298,773
  • Shaukhat Ali Khan

    Director Strategic Information

    Total calculated
    $289,581
    From this org
    $235,091
    From related orgs
    $0
    Other
    $54,490
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $235,091
    Bonus
    $0
    Other
    $0
    Deferred
    $44,098
    Nontaxable benefits
    $10,392
    Filer's total
    $289,581
  • Louisa Chaubert

    DIRECTOR OF FINANCE (THRU 12/23)

    Total calculated
    $103,443
    From this org
    $95,808
    From related orgs
    $0
    Other
    $7,635
    Hours/week
    0

    Schedule J breakdown matched by us

    Base
    $0
    Bonus
    $0
    Other
    $95,808
    Deferred
    $7,635
    Nontaxable benefits
    $0
    Filer's total
    $103,443

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Compensation survey or study
  • 3 · Approval by the board or compensation committee
  • 4a · Severance or change-of-control payment

Answered no

  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

Schedule J, Part III
The following individuals received severance payments in 2024: -Sharon Saacks received a severance payment of $85,006 in 2024. -Louisa Chaubert received a severance payment of $95,808 in 2024.

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

  • LABORATORY STRENGTHENING TO SUPPORT CLINICAL CARE AND RESEARCH

  • DIAGNOSTIC CONSULTING NETWORK

    $410,848

    DEVELOPMENT OF DIAGNOTIC TESTS

  • Clinton Health Access Initiative Inc

    $288,213

    TO SUPPORT TB ELIMINATION EFFORTS

  • PUBLICATION OF JOURNAL SUPPLEMENT

  • QUANTIGEN

    $40,570

    ACCELERATING TOOLS TO DRIVE TUBERCULOSIS DETECTION

  • GENOMICS TRAININGS. SUPPORTING THE AFRICA CDC WORKFORCE DEVELOPMENT EFFORT FOR PATHOGEN GENOMIC SURVEILLANCE

  • DIMAGI INC

    $30,457

    PRODUCTION OF MOBILE PHONE APPS THAT COLLECTS DATA FROM RAPID VITRO DIAGNOSTIC TEST AND THAT CAN AID AN RDT USER IN INTERPRETING THE TEST RESULTS

  • DRIVING EQUITABLE ACCESS TO TESTING IN LMICS THROUGH EFFECTIVE AND AFFORDABLE TESTS AND INFRASTRUCTURE

  • Drugs & Diagnostics for Tropical Diseases

    $10,011

    RAPID DIAGNOSTIC TESTING FOR BURULI ULCER

  • PROJECT AGREEMENT WITH HARVARD FOR SEQ&TREAT MUTATIONS CATALOGUE WORK

The 10 largest by cash amount. The API serves every itemized grant.

Activities outside the United States

From Schedule F of this return, as filed.

Offices (line 3c)
3
Employees, agents and contractors (line 3c)
210
Expenditures and investments (line 3c)
$52,547,847

At most 25 lines of each part are listed here. Schedule F names no grantee, so each line is a region and its money.

Activities by region (Part I)

Region Offices Employees Activity Specific services Expenditures
Sub-Saharan Africa 1 24 Program Services LABORATORY STRENGTHENING EVALUATION WORK $11,437,079
South Asia 0 0 Program Services LABORATORY STRENGTHENING EVALUATION WORK $2,838,911
East Asia and the Pacific 1 7 Program Services LABORATORY STRENGTHENING EVALUATION WORK $2,516,239
Europe (Including Iceland and Greenland) 1 179 Program Services LABORATORY STRENGTHENING EVALUATION WORK $34,190,111
South America 0 0 Program Services LABORATORY STRENGTHENING EVALUATION WORK $718,880
North America (Canada & Mexico only) 0 0 Program Services LABORATORY STRENGTHENING EVALUATION WORK $536,256
Russia and Neighboring States 0 0 Program Services LABORATORY STRENGTHENING EVALUATION WORK $78,098
Middle East and North Africa 0 0 Program Services LABORATORY STRENGTHENING EVALUATION WORK $191,790
Central America and the Caribbean 0 0 Program Services LABORATORY STRENGTHENING EVALUATION WORK $40,483

Grants to organizations, by region (Part II)

The purpose of each grant is not shown.

Region Cash grants Manner of disbursement Noncash assistance Noncash description Valuation
Sub-Saharan Africa $5,538,205 ELEC FD TRAN — N/A N/A
South Asia $204,033 ELEC FD TRAN — N/A N/A
East Asia and the Pacific $866,217 ELEC FD TRAN — N/A N/A
Europe (Including Iceland and Greenland) $4,581,949 ELEC FD TRAN — N/A N/A
South America $532,607 ELEC FD TRAN — N/A N/A
Russia and Neighboring States $54,879 ELEC FD TRAN — N/A N/A
Middle East and North Africa $27,033 ELEC FD TRAN — N/A N/A
Grantees recognized as charities or with a 501(c)(3) equivalency letter (Part II line 2)
52
Other grantees (Part II line 3)
57
Transferred property to a foreign corporation during the year (line 1)
No
Had an interest in a foreign trust (line 2)
No
Owned an interest in a foreign corporation (line 3)
No
Was a shareholder of a passive foreign investment company or qualified electing fund (line 4)
No
Owned an interest in a foreign partnership (line 5)
No
Had operations in or related to a boycotting country (line 6)
No

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

  • FIND INDIA

    PROGRAM SERVICES · IN · controlled entity

    Directly controlled by FIND SWISS

  • FIND DX NPC

    PROGRAM SERVICES · SF · controlled entity

    Directly controlled by FIND SWISS

  • FIND DX KENYA

    PROGRAM SERVICES · KE · controlled entity

    Directly controlled by FIND SWISS

Provenance

Return type
form_990
Tax year
2024
Filed
17 November 2025
IRS schema version
2024v5.1
Source object
202523219349318337

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.